Anabolic Therapy in Postmenopausal Osteoporosis

Summary

In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.

Timeline

Start

2022-03-24

Primary completion

2027-10-01

Completion

2027-11-01

Publications

• Leder BZ, Ramchand SK, Jordan M, Ryan S, Patnaik A, Lee H, Tsai JN. 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. Lancet Diabetes Endocrinol. 2026 Mar;14(3):216-222. doi: 10.1016/S2213-8587(25)00319-5. Epub 2026 Jan 29.

Drugs

Indications